Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.
Latest from Mandy Jackson
Bristol’s CEO Christopher Boerner says business development is the company’s biggest spending priority as analysts raise concerns about growth, citing a need for BMS to do more deals.
Bristol Myers Squibb’s first quarter revenue beat consensus and the company raised its 2025 guidance, even when including the impact of Chinese tariffs on US products.
Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.
As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.